Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     


Real-time Estimate Cboe BZX  -  01:33:29 2023-02-01 pm EST
139.68 USD   -0.20%
11:28aJP Morgan Asset Management's Timber-Investing Business Buys Commercial Forests for $500 Million
09:12aNYC Comptroller And Pension Funds Advocate For Banks To Establish Interim Absolute GhG Emissions Targets
02:11aTrading to be transformed by AI, say experts
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Dr. Cheryl Pegus, former Walmart EVP of Health & Wellness, Joins Morgan Health

11/21/2022 | 07:03am EST

Dr. Cheryl Pegus, a nationally-recognized leader for her work to deliver affordable, high-quality care to millions of Americans, will join Morgan Health to support the organization’s strategic investments and broader efforts to improve the quality, affordability and equity of health care.

Dr. Pegus joins Morgan Health from Walmart where she served as Executive Vice President for Health & Wellness. In her role, Dr. Pegus established Walmart as a formidable force in health care innovation and transformation. During her tenure, she launched notable consumer health programs designed to raise the standard of care for millions of Americans, including the roll-out of ReliOn insulin, which has saved customers more than $15 million on the cost of their insulin. She played a foundational role in broadening access to critical telehealth services across Walmart’s communities and worked to expand the footprint of Walmart’s retail Health Centers across major markets. She also oversaw the company’s pandemic response with the Health & Wellness team administering COVID vaccines to tens of millions of customers and associates.

Dr. Pegus will work closely with Dan Hartman and Jeff Ries, who lead Morgan Health’s ventures and investment efforts. As part of its mission to improve employer-sponsored health care, Morgan Health is investing $250 million of JPMorgan Chase & Co. capital to help scale promising companies focused on driving greater accountability in health care. To date, Morgan Health has deployed $105mm in four early-stage companies: Vera Whole Health, Embold Health, Centivo and LetsGetChecked.

Building on Morgan Health’s accountable care strategy, Dr. Pegus will help inform the team’s renewed focus on population-based health initiatives, including investing in and scaling promising new care delivery models designed to improve health outcomes, particularly among diverse populations. In addition, she will help Morgan Health advance its work and strategic investments dedicated to addressing gaps in mental and behavioral health, diabetes, heart disease and other chronic conditions among enrollees.

“Cheryl is one of the most respected leaders in health care and brings clinical and health care business expertise that will help accelerate the next phase of Morgan Health’s strategy around population health,” Dan Mendelson, CEO of Morgan Health, said. “She is also a cardiologist and health equity expert and will play a critical role in our work to invest in and scale companies that are making a meaningful difference in reversing the trend of chronic disease, particularly diabetes and heart disease, across the commercial market. She recognizes the opportunity that we have to improve health outcomes for our employees and the more than 150 million Americans who depend on employer-sponsored insurance.”

“Health care innovation continues to be very much needed, and I am excited to support this incredible Morgan Health team in accelerating offerings that improve outcomes,” Dr. Pegus said. “Moving new science into practice, supporting consumers in understanding what’s available and needed to stay healthy, while assisting health care professionals in doing our best work can deliver on the Quadruple Aim.”

Dr. Pegus brings more than 20 years of experience across the health sector to support Morgan Health’s vision and mission. Prior to joining Walmart, Dr. Pegus served as President of Consumer Solutions and Chief Medical Officer for Cambia Health Solutions. She also served as the first chief medical officer at Walgreens and as General Manager and Chief Medical Officer for SymCare Personalized Health Solutions, a diabetes-focused division of Johnson & Johnson. Dr. Pegus also had roles at Pfizer, where she focused on the development of clinical protocols and early disease management programs, and Aetna, where her work supported a focus on wellness, women's health, health equity initiatives and predictive analytics. She began her career in private practice as a cardiologist and previously served as board chair for the Association of Black Cardiologists.

In addition to her role at Morgan Health, Dr. Pegus will continue to serve as a senior advisor to Walmart and will be joining Atria. Dr. Pegus is co-founder of A New Beat and has served on the board of the American Heart Association as well as public and private companies.

About JPMorgan Chase
J.P. Morgan is a global leader in financial services, offering solutions to the world's most important corporations, governments and institutions in more than 100 countries. We also lead volunteer service activities for employees in local communities by utilizing our many resources, including those that stem from access to capital, economies of scale, global reach and expertise.

About Morgan Health
Morgan Health is a JPMorgan Chase business unit focused on improving employer-sponsored health care. Through its investments and the advancement of accountable care, Morgan Health is working to improve the quality, equity and affordability of employer-sponsored health care for JPMorgan Chase employees, their families and the U.S. health system. The business is led by Dan Mendelson, CEO of Morgan Health, reporting to Peter Scher, Vice Chairman of JPMorgan Chase & Co. and a member of the firm’s Operating Committee. Morgan Health is headquartered in Washington, D.C. Visit www.morganhealth.com.

ę Business Wire 2022
All news about JPMORGAN CHASE & CO.
11:28aJP Morgan Asset Management's Timber-Investing Business Buys Commercial Forests for $500..
09:12aNYC Comptroller And Pension Funds Advocate For Banks To Establish Interim Absolute GhG ..
02:11aTrading to be transformed by AI, say experts
01/31Fed Will Cut Rates This Year, JPMorgan's Kennedy Says
01/31J.P. Morgan Asset Management Appoints Michael Conrath as Chief Retirement Strategist
01/31Biggest Market Risk Is No US Recession, Says JPM's Bell
01/30Deutsche Bank Interested in Financing Serie A's Media Business
01/30Bank of America Appoints Former JPMorgan Executive Alexandra Johnson Head of Innovation..
01/30JPMorgan Chase & Co. Working With KPMG to Review Oversight of Traders
01/30Citigroup Hiring JPMorgan's Cyril Besseddik to Head Healthcare Companies in EMEA Market..
More news
Analyst Recommendations on JPMORGAN CHASE & CO.
More recommendations
Financials (USD)
Sales 2022 129 B - -
Net income 2022 34 853 M - -
Net Debt 2022 - - -
P/E ratio 2022 12,0x
Yield 2022 2,86%
Capitalization 411 B 411 B -
Capi. / Sales 2022 3,17x
Capi. / Sales 2023 2,92x
Nbr of Employees 293 723
Free-Float 70,7%
Duration : Period :
JPMorgan Chase & Co. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JPMORGAN CHASE & CO.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 139,96 $
Average target price 156,44 $
Spread / Average Target 11,8%
EPS Revisions
Managers and Directors
James Dimon Director
Daniel E. Pinto President & Chief Operating Officer
Jeremy Barnum Chief Financial Officer & Executive VP
Lori A. Beer Global Chief Information Officer
Rohan Amin Chief Information Security Officer